Neurotech Pharmaceuticals Inc., whose executive chairman is well-known Orange County executive Jim Mazzo, announced that it received FDA approval for its treatment of a type of macular telangiectasia (MacTel), a neurodegenerative retinal disease.
The Rhode Island-based biotech’s treatment, ENCELTO, is the first and only FDA-approved treatment available for the disease, which causes progressive and irreversible vision loss, according to the company.
“Today marks an extraordinary milestone for patients, the retina community, and Neurotech,” Neurotech Chief Executive Richard Small said in a statement.
Neurotech expects ENCELTO to be available to U.S. patients starting June 2025.
